{"title":"The burden of prostate cancer and metastatic prostate cancer in Italy in 2024.","authors":"Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani","doi":"10.1097/CEJ.0000000000000960","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The epidemiologic scenario of prostate cancer (PC) is changing rapidly. The present study updates to 2024 the estimates of PC in Italy, including incident and prevalent cases, deaths, and metastatic PC (mPC), which is further subdivided into de novo mPC (metastasis detected at diagnosis) and recurrent mPC (metachronous metastasis).</p><p><strong>Methods: </strong>The study was based on updated data from the Italian Network of Cancer Registries and the National Institute of Statistics and the age-specific short-term PC projections made available by the International Agency for Cancer Research. For mPC, we applied the age-specific ratios between deaths and estimated de novo and recurrent mPCs for the USA to the Italian age-specific deaths.</p><p><strong>Results: </strong>In Italy, in 2024, we expect 8400 PC deaths, approximately 39 000 new diagnoses, 4900 of whom are diagnoses of mPC, and almost 670 000 prevalent cases, about 36 000 of whom are mPCs.</p><p><strong>Conclusion: </strong>These estimates provide updated and realistic information to policy makers, clinicians, and the community to properly address the needs of patients with PC in Italy from diagnosis to end-of-life care.</p>","PeriodicalId":11830,"journal":{"name":"European Journal of Cancer Prevention","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CEJ.0000000000000960","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The epidemiologic scenario of prostate cancer (PC) is changing rapidly. The present study updates to 2024 the estimates of PC in Italy, including incident and prevalent cases, deaths, and metastatic PC (mPC), which is further subdivided into de novo mPC (metastasis detected at diagnosis) and recurrent mPC (metachronous metastasis).
Methods: The study was based on updated data from the Italian Network of Cancer Registries and the National Institute of Statistics and the age-specific short-term PC projections made available by the International Agency for Cancer Research. For mPC, we applied the age-specific ratios between deaths and estimated de novo and recurrent mPCs for the USA to the Italian age-specific deaths.
Results: In Italy, in 2024, we expect 8400 PC deaths, approximately 39 000 new diagnoses, 4900 of whom are diagnoses of mPC, and almost 670 000 prevalent cases, about 36 000 of whom are mPCs.
Conclusion: These estimates provide updated and realistic information to policy makers, clinicians, and the community to properly address the needs of patients with PC in Italy from diagnosis to end-of-life care.
期刊介绍：
European Journal of Cancer Prevention aims to promote an increased awareness of all aspects of cancer prevention and to stimulate new ideas and innovations. The Journal has a wide-ranging scope, covering such aspects as descriptive and metabolic epidemiology, histopathology, genetics, biochemistry, molecular biology, microbiology, clinical medicine, intervention trials and public education, basic laboratory studies and special group studies. Although affiliated to a European organization, the journal addresses issues of international importance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
